At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 301 enrolled
Drug / intervention
Radiopaque Etonogestrel Implantdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Non-Controlled Multicenter Trial to Evaluate the Insertion Characteristics of the Radiopaque Etonogestrel Implant Using a Next Generation Applicator
In Brief
A Phase 3 clinical trial evaluating Radiopaque Etonogestrel Implant for Contraception. Completed, enrolled 301 participants.
Detailed Summary
The primary purpose of this study is to evaluate the use of the next generation applicator and its instructions for proper insertion of the Radiopaque Implant. Secondary objectives include: evaluation of implant removal, evaluation of the overall contraceptive efficacy and safety of the Radiopaque Implant, assessment of x -ray visibility of the Radiopaque Implant, and to assess participant expectations and satisfaction with the Radiopaque Implant.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsContraception
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2007
First PostedFeb 2008
Primary CompletionOct 2010
TodayJul 2026
First PostedFeb 21, 2008
Enrollment StartMar 1, 2007
Primary CompletionOct 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 18.4 years ago
Interventions
Radiopaque Etonogestrel Implantdrug
One implant inserted for a 3-year treatment period